Last reviewed · How we verify
Traumatic Skin Lesion Streptococcus Pyogenes Infection — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Bactroban | MUPIROCIN | GSK | RNA Synthetase Inhibitor Antibacterial | Isoleucine--tRNA ligase, cytoplasmic | 1987-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- GSK · 1 drug in Traumatic Skin Lesion Streptococcus Pyogenes Infection
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Traumatic Skin Lesion Streptococcus Pyogenes Infection:
- Traumatic Skin Lesion Streptococcus Pyogenes Infection treatment updates — RSS
- Traumatic Skin Lesion Streptococcus Pyogenes Infection treatment updates — Atom
- Traumatic Skin Lesion Streptococcus Pyogenes Infection treatment updates — JSON
Cite this brief
Drug Landscape (2026). Traumatic Skin Lesion Streptococcus Pyogenes Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/traumatic-skin-lesion-streptococcus-pyogenes-infection. Accessed 2026-06-10.
Related
- Traumatic Skin Lesion Streptococcus Pyogenes Infection full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing